It is estimated that there will be over 65,000 new cases of cancers of the kidney and renal pelvis in 2013 and about 13,000 deaths. The SPORE in renal cancer, which began in 2001, is a highly integrated program focusing on tumor genetics, minimally invasive therapy, and immune immunotherapy for renal cell carcinoma. This SPORE approaches the therapeutic intervention of this disease from several different angles, including angiogenesis inhibition, immune modulation, and inhibition of specific cancer-related molecular pathways. A notable accomplishment of this SPORE is its identification of a gene whose inactivation accounts for approximately one-third of Wilms tumors, a common pediatric tumor.
The renal SPORE fosters collaborations among the national experts in renal cancer, and generates resources and research opportunities which otherwise would not exist for the scientific community. The leadership of the Renal SPORE engages experts from throughout the United States and abroad through the Kidney Cancer Association, Society for Biological Therapy, the Cytokine Working Group or through collaborations in industry-sponsored trials. The SPORE offers its expertise and facility as a resource for correlative biomarkers for a number of nationally conducted clinical trials and also conducts national meetings on topics focused on different aspects of translational research in kidney cancer.
Michael B. Atkins, MD [Click Here]
Deputy Chief, Division of Hematology/Oncology
Beth Israel Deaconess Medical Center/Beth Israel Deaconess Cancer Center
Dana Farber/Harvard Cancer Center
Masco Bldg, Rm 412
375 Longwood Ave
For more information on this specific SPORE’s institution, please visit: